Differential expression of α-synuclein isoforms in dementia with Lewy bodies

被引:58
作者
Beyer, K
Lao, JI
Carrato, C
Mate, JL
López, D
Ferrer, I
Ariza, A [1 ]
机构
[1] Autonomous Univ Barcelona, Hosp Univ Germans Trias & Pujol, Dept Pathol, Barcelona 08916, Spain
[2] Labs Dr Echevarne, Dept Med & Mol Genet, Barcelona, Spain
[3] Univ Barcelona, Neurol Tissue Bank, Barcelona, Spain
[4] ICS Inst Neuropathol, Barcelona, Spain
关键词
alpha-synuclein isoforms; Alzheimer disease; competimer technology; dementia with Lewy bodies; mRNA expression;
D O I
10.1111/j.1365-2990.2004.00572.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dementia with Lewy bodies (DLB) is characterized by the widespread presence of Lewy bodies (LBs) in the brain. alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential expression in the brain. We compared alpha-synuclein 112 and alpha-synuclein 140 expression levels in the prefrontal cortices of six DLB patients, eight Alzheimer disease (AD) patients, and six control subjects. Relative alpha-synuclein 112 and alpha-synuclein 140 expression levels were determined by real-time polymerase chain reaction with competimer technology using a LightCycler System. Whereas total alpha-synuclein levels were just marginally elevated in DLB in comparison with the other groups, alpha-synuclein 112 was seen to be markedly increased in DLB compared with AD cases and controls. In contrast, alpha-synuclein 140 levels were significantly diminished in both neurodegenerative disorders in comparison with controls. These results show differential overexpression of alpha-synuclein 112 in DLB, a finding that could be of importance in DLB pathogenesis.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 32 条
  • [1] Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
    Abeliovich, A
    Schmitz, Y
    Fariñas, I
    Choi-Lundberg, D
    Ho, WH
    Castillo, PE
    Shinsky, N
    Verdugo, JMG
    Armanini, M
    Ryan, A
    Hynes, M
    Phillips, H
    Sulzer, D
    Rosenthal, A
    [J]. NEURON, 2000, 25 (01) : 239 - 252
  • [2] Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies
    Arima, K
    Hirai, S
    Sunohara, N
    Aoto, K
    Izumiyama, Y
    Uéda, K
    Ikeda, K
    Kawai, M
    [J]. BRAIN RESEARCH, 1999, 843 (1-2) : 53 - 61
  • [3] Baba M, 1998, AM J PATHOL, V152, P879
  • [4] Stabilization of α-synuclein secondary structure upon binding to synthetic membranes
    Davidson, WS
    Jonas, A
    Clayton, DF
    George, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) : 9443 - 9449
  • [5] Conformational properties of α-synuclein in its free and lipid-associated states
    Eliezer, D
    Kutluay, E
    Bussell, R
    Browne, G
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2001, 307 (04) : 1061 - 1073
  • [6] Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO
  • [7] 2-0
  • [8] Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro
    Giasson, BI
    Uryu, K
    Trojanowski, JQ
    Lee, VMY
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (12) : 7619 - 7622
  • [9] Filamentous nerve cell inclusions in neurodegenerative diseases
    Goedert, M
    Spillantini, MG
    Davies, SW
    [J]. CURRENT OPINION IN NEUROBIOLOGY, 1998, 8 (05) : 619 - 632
  • [10] Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
    Irizarry, MC
    Growdon, W
    Gomez-Isla, T
    Newell, K
    George, JM
    Clayton, DF
    Hyman, BT
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1998, 57 (04) : 334 - 337